Lung Oat Cell Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LNG020 MIFTS: 53	Lung Oat Cell Carcinoma Categories: Cancer diseases, Respiratory diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Lung Oat Cell Carcinoma

MalaCards integrated aliases for Lung Oat Cell Carcinoma:

Name: Lung Oat Cell Carcinoma ¹¹ ⁵ ¹⁴

Carcinoma, Small Cell ⁴³

Oat Cell Carcinoma ¹¹

Carcinoma Oat Cell ⁵³

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:5411

MeSH ⁴³ D018288

NCIt ⁴⁹ C3915

SNOMED-CT ⁶⁸ 11010461000119101

UMLS ⁷¹ C0262584

Sources

Summaries for Lung Oat Cell Carcinoma

MalaCards based summary: Lung Oat Cell Carcinoma, also known as carcinoma, small cell, is related to esophagus small cell carcinoma and prostate small cell carcinoma. An important gene associated with Lung Oat Cell Carcinoma is RB1 (RB Transcriptional Corepressor 1), and among its related pathways/superpathways are Disease and Cytokine Signaling in Immune system. The drugs BCG vaccine and Atezolizumab have been mentioned in the context of this disorder. Affiliated tissues include lung, cervix and prostate, and related phenotypes are nervous system and neoplasm

Sources

Related Diseases for Lung Oat Cell Carcinoma

Diseases related to Lung Oat Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 521)

#	Related Disease	Score	Top Affiliating Genes
1	esophagus small cell carcinoma	32.4	PIK3CA ENO2
2	prostate small cell carcinoma	31.8	SYP ENO2
3	gallbladder small cell carcinoma	31.4	SYP ENO2 CHGA
4	carcinoid tumors, intestinal	30.4	SYP ENO2 CHGA
5	squamous cell carcinoma	30.4	TP53 RB1 PTEN PIK3CA AKT1
6	inappropriate adh syndrome	30.3	POMC ENO2 AVP
7	carcinoid syndrome	30.2	SYP ENO2 CHGA
8	small cell carcinoma	30.0	TP53 SYP PTEN ENO2 CHGA
9	sarcoma	30.0	TP53 RB1 PIK3CA ENO2
10	gallbladder adenocarcinoma	30.0	TP53 SYP CHGA
11	papilloma	29.9	TP53 RB1 PTEN AKT1
12	bladder small cell carcinoma	29.8	SYP ENO2
13	esophageal cancer	29.8	TP53 RB1 PTEN PIK3CA AKT1
14	acquired immunodeficiency syndrome	29.8	TP53 POMC B2M
15	myeloma, multiple	29.8	TP53 RB1 PIK3CA B2M AKT1
16	mismatch repair cancer syndrome	29.8	TP53 PTEN PIK3CA
17	diffuse gastric cancer	29.8	TP53 PTEN PIK3CA
18	ductal carcinoma in situ	29.8	TP53 PTEN PIK3CA AKT1
19	cholangiocarcinoma	29.8	TP53 PTEN PIK3CA AKT1
20	transitional cell carcinoma	29.7	TP53 PTEN ENO2
21	large cell carcinoma	29.7	TP53 SYP ENO2 CHGA
22	adenocarcinoma	29.6	TP53 RB1 PTEN PIK3CA CHGA AKT1
23	gallbladder cancer	29.6	TP53 RB1 PTEN PIK3CA AKT1
24	conn's syndrome	29.5	TP53 SYP POMC CHGA AVP
25	head and neck cancer	29.5	TP53 PTEN PIK3CA AKT1
26	merkel cell carcinoma	29.4	SYP ENO2 CHGA
27	lung cancer susceptibility 3	29.4	TP53 RB1 PIK3CA B2M AKT1
28	neuroendocrine carcinoma	29.4	SYP PTEN ENO2 CHGA
29	bladder urothelial carcinoma	29.4	TP53 RB1 PTEN PIK3CA AKT1
30	squamous cell carcinoma, head and neck	29.3	TP53 RB1 PTEN PIK3CA B2M AKT1
31	multiple endocrine neoplasia	29.3	SYP POMC CHGA
32	tubular adenocarcinoma	29.2	SYP ENO2 CHGA
33	thyroid gland medullary carcinoma	29.1	SYP POMC CHGA
34	wilms tumor 1	29.0	TP53 SYP PTEN ENO2 AKT1
35	lung benign neoplasm	29.0	TP53 SYP RB1 ENO2 CHGA
36	large cell neuroendocrine carcinoma	29.0	TP53 SYP ENO2 CHGA
37	lung large cell carcinoma	29.0	TP53 SYP ENO2 CHGA
38	mixed cell type cancer	29.0	TP53 SYP PTEN PIK3CA ENO2 CHGA
39	islet cell tumor	29.0	SYP POMC ENO2 CHGA
40	pheochromocytoma	29.0	SYP POMC ENO2 CHGA
41	melanoma	28.9	TP53 RB1 PTEN POMC PIK3CA ENO2
42	adenoma	28.6	TP53 SYP POMC PIK3CA CHGA AKT1
43	medulloblastoma	28.5	TP53 SYP RB1 PTEN PIK3CA ENO2
44	pancreatic cancer	28.5	TP53 SYP RB1 PTEN PIK3CA CHGA
45	lung cancer	28.4	TP53 SYP RB1 PTEN PIK3CA ENO2
46	suppression of tumorigenicity 12	28.4	TP53 SYP PTEN PIK3CA ENO2 CHGA
47	neuroblastoma	28.4	TP53 SYP PTEN PIK3CA ENO2 CHGA
48	small cell cancer of the lung	27.5	TP53 SYP RB1 PTEN POMC PIK3CA
49	nervous system disease	27.5	TP53 SYP RB1 PTEN POMC PIK3CA
50	trachea carcinoma	10.4

Graphical network of the top 20 diseases related to Lung Oat Cell Carcinoma:

Sources

Symptoms & Phenotypes for Lung Oat Cell Carcinoma

MGI Mouse Phenotypes related to Lung Oat Cell Carcinoma:

⁴⁵ (show all 12)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	nervous system	MP:0003631	10.22	AKT1 AVP B2M CHGA ENO2 PIK3CA
2	neoplasm	MP:0002006	10.05	AKT1 B2M PIK3CA POMC PTEN RB1
3	no phenotypic analysis	MP:0003012	9.97	AVP CHGA PIK3CA POMC RB1 TP53
4	growth/size/body region	MP:0005378	9.97	AKT1 B2M CHGA ENO2 PIK3CA POMC
5	renal/urinary system	MP:0005367	9.93	AVP CHGA POMC PTEN RB1 TP53
6	muscle	MP:0005369	9.91	AKT1 CHGA PIK3CA PTEN RB1 TP53
7	liver/biliary system	MP:0005370	9.88	AKT1 B2M POMC PTEN RB1 TP53
8	endocrine/exocrine gland	MP:0005379	9.86	AKT1 B2M CHGA PIK3CA POMC PTEN
9	adipose tissue	MP:0005375	9.85	AKT1 PIK3CA POMC PTEN RB1 TP53
10	cardiovascular system	MP:0005385	9.76	AKT1 B2M CHGA PIK3CA POMC PTEN
11	behavior/neurological	MP:0005386	9.61	AKT1 AVP ENO2 PIK3CA POMC PTEN
12	integument	MP:0010771	9.17	AKT1 B2M PIK3CA POMC PTEN RB1

Sources

Drugs & Therapeutics for Lung Oat Cell Carcinoma

Drugs for Lung Oat Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

BCG vaccine

Approved, Investigational

Phase 3

Atezolizumab

Approved, Investigational

Phase 2, Phase 3

1380723-44-3

Memantine

Approved, Investigational

Phase 3

41100-52-1, 19982-08-2

4054

Dopamine

Approved

Phase 3

62-31-7, 51-61-6

681

Cisplatin

Approved

Phase 3

15663-27-1

2767 5702198 441203

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Etoposide

Approved

Phase 3

33419-42-0

36462

Belotecan

Investigational

Phase 3

256411-32-2

9824190

Vaccines

Phase 3

Epoetin Alfa

Phase 3

Hematinics

Phase 3

Immunologic Factors

Phase 2, Phase 3

Neurotransmitter Agents

Phase 3

Dopamine Agents

Phase 3

Antiparkinson Agents

Phase 3

Excitatory Amino Acid Antagonists

Phase 3

Etoposide phosphate

Phase 3

16760419

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

Somatostatin

Approved, Investigational

Phase 1, Phase 2

38916-34-6, 51110-01-1

53481605 16129706

Arsenic trioxide

Approved, Investigational

Phase 2

1327-53-3

518740

Vinorelbine

Approved, Investigational

Phase 2

71486-22-1

44424639 60780

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Temozolomide

Approved, Investigational

Phase 1, Phase 2

85622-93-1

5394

Irinotecan

Approved, Investigational

Phase 1, Phase 2

97682-44-5, 100286-90-6

60838

Lamivudine

Approved, Investigational

Phase 2

134678-17-4

60825

Rucaparib

Approved, Investigational

Phase 1, Phase 2

283173-50-2

9931954

Niraparib

Approved, Investigational

Phase 1, Phase 2

1038915-60-4

24958200

Erlotinib

Approved, Investigational

Phase 2

183319-69-9, 183321-74-6

176870

Lapatinib

Approved, Investigational

Phase 2

231277-92-2, 388082-78-8

208908

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Talazoparib

Approved, Investigational

Phase 2

1207456-01-6

135565082

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Prednisone

Approved, Vet_approved

Phase 2

53-03-2

5865

Methyltestosterone

Approved

Phase 2

58-18-4

6010

Testosterone undecanoate

Approved, Investigational

Phase 2

5949-44-0

21873174 65157

Testosterone enanthate

Approved

Phase 2

315-37-7

9416

Testosterone

Approved, Investigational

Phase 2

58-22-0

5408 6013

Nivolumab

Approved

Phase 2

946414-94-4

Ipilimumab

Approved

Phase 2

477202-00-9

Durvalumab

Approved, Investigational

Phase 2

1428935-60-7

Topotecan

Approved, Investigational

Phase 2

123948-87-8, 119413-54-6

60699 60700

Pomalidomide

Approved

Phase 1, Phase 2

19171-19-8

134780

Levoleucovorin

Approved, Experimental, Investigational

Phase 1, Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Pemetrexed

Approved, Investigational

Phase 1, Phase 2

150399-23-8, 137281-23-3

60843 446556 135565230

Gemcitabine

Approved

Phase 2

95058-81-4, 122111-03-9

60750

Bemiparin

Approved, Investigational

Phase 2

91449-79-5

Zoledronic acid

Approved

Phase 2

118072-93-8

68740

Picropodophyllin

Approved, Investigational

Phase 2

518-28-5, 477-47-4

10607 72435

Olaparib

Approved

Phase 2

763113-22-0

23725625

Interventional clinical trials:

(show top 50) (show all 139)

#	Name	Status	NCT ID	Phase	Drugs
1	Phase III Randomized Study of Hypofractionated vs Conventionally Fractionated Concurrent Chemo-radiotherapy for Limited Disease Small Cell Lung Cancer	Unknown status	NCT02688036	Phase 3
2	A Randomized Prospective Multicenter Trial of Belotecan/Cisplatin Versus Etoposide/Cisplatin in Patients With Previously Untreated, Extensive-stage Small-cell Lung Cancer	Completed	NCT00826644	Phase 3	Belotecan;Etoposide;Cisplatin
3	The SILVA Study: Survival in an International Phase III Prospective Randomized LD Small Cell Lung Cancer Vaccination Study With Adjuvant BEC2 and BCG	Completed	NCT00037713	Phase 3
4	A Placebo-Controlled Study on the Effect of Epoetin Alfa in Patients With Malignancy Receiving Chemotherapy	Completed	NCT00270166	Phase 3	epoetin alfa
5	Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)	Recruiting	NCT05058651	Phase 2, Phase 3	Carboplatin;Cisplatin;Etoposide
6	Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab	Recruiting	NCT03811002	Phase 2, Phase 3	Atezolizumab;Carboplatin;Cisplatin;Etoposide
7	MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)	Recruiting	NCT04155034	Phase 3
8	Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial	Recruiting	NCT04402788	Phase 2, Phase 3	Atezolizumab
9	Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases From Small Cell Lung Cancer	Recruiting	NCT04804644	Phase 3	Memantine Hydrochloride
10	REPLATINUM: A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer	Active, not recruiting	NCT05566041	Phase 3	RRx-001 + eLOOP Device;Cisplatin/carboplatin plus etoposide
11	A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer	Terminated	NCT03699956	Phase 3	Cisplatin/carboplatin plus etoposide
12	Phase 2 Study of Temozolomide as Maintenance Therapy After Initial Induction Chemotherapy in Small Cell Lung Cancer	Unknown status	NCT01900951	Phase 2	Temozolomide
13	Phase II Clinical Trial of Toripalimab (JS001), a Recombinant Humanized Anti-PD-1 Monoclonal PD1 Antibody, as Monotherapy for Patients With Small Cell Esophageal Carcinoma Who Failed Chemotherapy	Unknown status	NCT03811379	Phase 2	Toripalimab
14	Phase Ⅱ Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer	Unknown status	NCT01635400	Phase 2	Irinotecan
15	An Open-label Phase II Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of 200 mg i.v. BI 2536 Administered Every 21 Days in Patients With Sensitive Relapse Small Cell Lung Cancer	Completed	NCT00412880	Phase 2	BI 2536
16	A Phase I/II Study of Radiation Dose Intensity Concurrent With Chemotherapy For Limited Stage Small Cell Lung Cancer	Completed	NCT00126828	Phase 1, Phase 2
17	Phase II Trial of ALIMTA in Relapsed Small Cell Lung Cancer	Completed	NCT00191750	Phase 2	Pemetrexed
18	Phase I/II Study to Investigate the Safety, Tolerability, Efficacy and Pharmacokinetics of ZK 219477 in Combination With Cisplatin as First-line Therapy in Chemotherapy-naïve Patients With Extensive-disease (ED) Stage Small-cell Lung Cancer (SCLC)	Completed	NCT00359359	Phase 1, Phase 2	Sagopilone (BAY86-5302, ZK 219477);Cisplatin
19	Phase II Study of Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Patients With Limited Stage Small Cell Lung Cancer	Completed	NCT00308529	Phase 2	irinotecan;carboplatin;bevacizumab
20	A Phase II Trial of Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer	Completed	NCT00305942	Phase 2	Topotecan;carboplatin
21	Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of Intravenous Administration of SNS-595 in Patients With Advanced Small Cell Lung Cancer (SCLC)	Completed	NCT00298896	Phase 2	SNS-595
22	A Phase II Trial of Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer	Completed	NCT00294931	Phase 2	irinotecan;carboplatin;bevacizumab
23	A Phase II Study Of Higher Dose Weekly Topotecan In The Treatment Of Patients With Extensive Stage Small-Cell Lung Cancer	Completed	NCT00294190	Phase 2	Topotecan
24	A Phase II Trial of VInflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer	Completed	NCT00284154	Phase 2	Vinflunine
25	Phase II Study to Determine the Efficacy of OSI-211 (Liposomal Lurtotecan) Given on Days 1, 2 & 3 Every 3 Weeks in Patients With Recurrent Small Cell Lung Cancer	Completed	NCT00046787	Phase 2	OSI-211 (Liposomal Lurtotecan)
26	A Phase 1/2a, Open-label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEN-221 in Patients With Somatostatin Receptor 2 Expressing Advanced Cancers, Including Gastroenteropancreatic or Lung or Thymus or Other Neuroendocrine Tumors or Small Cell Lung Cancer or Large Cell Neuroendocrine Carcinoma of the Lung	Completed	NCT02936323	Phase 1, Phase 2	PEN-221
27	A Single Arm, Two-Stage Phase II Study of Arsenic Trioxide in Previously Treated Small Cell Lung Cancer	Completed	NCT01470248	Phase 2	Arsenic Trioxide
28	Combination Chemotherapy With or Without Maintenance Sunitinib Malate (NSC 736511) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/Randomized Phase II Study	Completed	NCT00453154	Phase 1, Phase 2	Carboplatin;Cisplatin;Etoposide;Sunitinib Malate
29	Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage	Completed	NCT00416455	Phase 1, Phase 2	ferumoxtran-10
30	Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer	Completed	NCT01642251	Phase 1, Phase 2	Cisplatin;Etoposide;Veliparib;Placebo
31	Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer	Completed	NCT00217633	Phase 2
32	A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix	Completed	NCT00309959	Phase 2	Paclitaxel Albumin-Stabilized Nanoparticle Formulation
33	A Clinical Trial of Increased Chest Radiotherapy Dose for Limited Stage Small Cell Lung Cancer	Completed	NCT00907569	Phase 2
34	A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)	Completed	NCT02489903	Phase 2	RRx-001;Cisplatin;Etoposide;Carboplatin;Irinotecan;Vinorelbine;Doxil;Gemcitabine;Taxane;Paclitaxel;Nab-Paclitaxel;Pemetrexed
35	A Phase II Evaluation of ABT-888 (NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix	Completed	NCT01266447	Phase 2	Topotecan Hydrochloride;Veliparib
36	PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX	Completed	NCT02164461	Phase 1, Phase 2
37	An Open Label Phase I/II Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer	Completed	NCT01505868	Phase 1, Phase 2	Cabazitaxel;Carboplatin
38	A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors	Recruiting	NCT03333616	Phase 2	Ipilimumab;Nivolumab
39	Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Cancers	Recruiting	NCT03554473	Phase 1, Phase 2	M7824;Topotecan;Temozolomide
40	Open Label Study of Single Dose Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy	Recruiting	NCT00100256	Phase 1, Phase 2	Rhenium (Re 188 P2045, BAY86-5284)
41	A Phase II Trial of Lamivudine in Combination With Chemoimmunotherapy in Patients With Extensive Stage SCLC	Recruiting	NCT04696575	Phase 2	Carboplatin;Etoposide;Lamivudine
42	Phase II Clinical Trial of Durvalumab (MEDI4736) and Topotecan or Lurbinectedin in Patients With Relapsed Extensive Stage Small Cell Lung Cancer Previously Treated With Chemotherapy and Immunotherapy	Recruiting	NCT04607954	Phase 2	Lurbinectedin;Topotecan Hydrochloride
43	Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix	Recruiting	NCT05063916	Phase 2	AK104
44	Phase I/II Trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers	Recruiting	NCT04209595	Phase 1, Phase 2	PLX038;Rucaparib
45	A Study of Erdafitinib in Castration-Resistant Prostate Cancer Patients Evaluating Markers of Bone Remodeling and FGF Signaling in Plasma and Bone Marrow	Recruiting	NCT04754425	Phase 2	Erdafitinib
46	A Phase I/II Trial of PARP Inhibition, Radiation, and Immunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - PRIO Trial	Recruiting	NCT04728230	Phase 1, Phase 2	Carboplatin;Etoposide;Olaparib
47	Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases, Administered in Combination With the Anti-Programmed Cell Death 1 Monoclonal Antibody Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype	Recruiting	NCT03910660	Phase 1, Phase 2	BXCL701 plus Pembrolizumab;BXCL701 monotherapy
48	A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)	Recruiting	NCT03866382	Phase 2	Cabozantinib S-malate
49	An Open-Label Phase 1b Dose-Finding Trial Evaluating the Safety of Niraparib and Temozolomide and Atezolizumab in Participants With Advanced Solid Tumors and Expansion to a Phase 2 Trial Comparing the Effects of Niraparib and Temozolomide Plus Atezolizumab vs. Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy (TRIO-US L-06)	Recruiting	NCT03830918	Phase 1, Phase 2	Niraparib;Temozolomide
50	Niraparib (PARP Inhibitor) Plus Dostarlimab (Anti-PD1) for Small Cell Lung Cancer (SCLC) and Other High-Grade Neuroendocrine Carcinomas (NEC)	Recruiting	NCT04701307	Phase 2	Niraparib

Search NIH Clinical Center for Lung Oat Cell Carcinoma

Cochrane evidence based reviews: carcinoma, small cell

Sources

Genetic Tests for Lung Oat Cell Carcinoma

Sources

Anatomical Context for Lung Oat Cell Carcinoma

Organs/tissues related to Lung Oat Cell Carcinoma:

MalaCards : Lung, Cervix, Prostate, Lymph Node, Thymus, Brain, Bone Marrow

Sources

Publications for Lung Oat Cell Carcinoma

Articles related to Lung Oat Cell Carcinoma:

(show top 50) (show all 754)

#	Title	Authors	PMID	Year
1	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. ⁵	Chang MT...Taylor BS	26619011	2016
2	Prospective enterprise-level molecular genotyping of a cohort of cancer patients. ⁵	MacConaill LE...Lindeman NI	25157968	2014
3	Molecular profiling of small cell lung cancer in a Japanese cohort. ⁵	Wakuda K...Yamamoto N	24657128	2014
4	Oncogenic point mutations in the human retinoblastoma gene: their application to genetic counseling. ⁵	Yandell DW...Dryja TP	2594029	1989
5	Neurophysins as markers of vasopressin and oxytocin release. A study in carcinoma of the lung. ⁵³ ⁶²	Legros JJ...Gharib C	1966564	1990
6	A Spoonful of Eponyms Helps the Pathology Go Down: Using Food Eponyms and Visual Mnemonics in Preclinical Pathology Education. ⁶²	Seto C...Zayat V	35154897	2022
7	Oat Cell Carcinoma Lung Presenting as Chest Wall Swelling. ⁶²	Wadhwa M...Singla G	34603878	2021
8	Managing Severe Dysgeusia and Dysosmia in Lung Cancer Patients: A Systematic Scoping Review. ⁶²	Spencer AS...Ravasco P	34881185	2021
9	Calcitonin-Negative Neuroendocrine Carcinoma of the Thyroid Gland: Case Report and Literature Review. ⁶²	Fernandez-Ferreira R...Cortes-Gonzalez R	33776692	2021
10	Nerve root metastasis of gastric adenocarcinoma: A case report and review of the literature. ⁶²	Di Sibio A...Masciocchi C	31302320	2019
11	Oat-cell carcinoma of the tongue. ⁶²	Aguilar F...Bernal-Escote X	26956201	2016
12	Small cell carcinoma of the urinary bladder: changing trends in the current literature. ⁶²	Erdem GU...Zengin N	26889739	2016
13	The role of immunohistochemistry in the analysis of the spectrum of small round cell tumours at a tertiary care centre. ⁶²	D'cruze L...Kuruvilla S	23998069	2013
14	Squamous cell carcinoma lung with progressive systemic sclerosis. ⁶²	Kundu S...Chatterjee S	23781672	2012
15	Endoscopic ultrasound-guided biopsies for mediastinal lesions and lymph node diagnosis and staging. ⁶²	Ardengh JC...Parada AA	22179163	2011
16	Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features. ⁶²	Alberti C	21232206	2010
17	Survival in a patient with severe paraneoplastic hyponatremia: a case report. ⁶²	Walker GV...Peterson MC	18928542	2008
18	Merkel cell carcinoma: treatment with bleomycin. ⁶²	Ely H...Pascucci A	19061585	2008
19	[Small (oat)-cell carcinoma of the gastrointestinal tract]. ⁶²	Bravo E...Sarabia S	18341909	2008
20	Merkel cell carcinoma of the upper extremity: case report and an update. ⁶²	Papamichail M...Digalakis M	18328106	2008
21	A note from history: the saga of carcinoid and oat-cell carcinoma. ⁶²	Hajdu SI...Tang P	18988939	2008
22	Cancer-associated retinopathy (CAR) with electronegative ERG: a case report. ⁶²	Goetgebuer G...Leroy BP	17721792	2008
23	[Oat-cell carcinoma of the esophagus: presentation of two cases and literature review]. ⁶²	Linan Padilla A...Hernandez de la Torre JM	17973588	2007
24	Isolated frontal disequilibrium as presenting form of anti-Hu paraneoplastic encephalomyelitis. ⁶²	Compta Y...Graus F	17266086	2007
25	F-18 FDG PET imaging of urinary bladder oat cell carcinoma with widespread osseous metastases. ⁶²	Iagaru A...Segall G	16855436	2006
26	[Oat cell carcinoma of the common bile duct]. ⁶²	Viana Miguel MM...Santamaria Garcia JL	16796953	2006
27	Oat cell carcinoma of the oesophagus--a case report and review of literature. ⁶²	Simon EG...Jayanthi V	16498759	2005
28	[Diabetes insipidus in a patient with small-cell lung cancer: a paradox?]. ⁶²	Schleich F...Legros JJ	16392186	2005
29	[Neuroendocrine carcinomas of the cervix]. ⁶²	Schmidt D...Kommoss F	15915327	2005
30	Extra-pulmonary oat cell carcinoma: report of two cases. ⁶²	Badger SA...Panesar KJ	16022138	2005
31	(18)FDG PET in primary oat cell carcinoma of the esophagus. ⁶²	Basu S...Nair N	15805695	2005
32	Primary oat cell carcinoma of the breast: imaging features. ⁶²	Mariscal A...Gallart AM	15385324	2004
33	Small-cell carcinomas of the gastrointestinal tract: a review. ⁶²	Brenner B...Kelsen DP	15226341	2004
34	Progressive encephalomyelitis with rigidity: a paraneoplastic presentation of oat cell carcinoma of the lung. Case report. ⁶²	Spitz M...Gabbai AA	15273862	2004
35	[Paraneoplastic syndromes in ENT surgery]. ⁶²	Scheuermann K...Delank KW	12682737	2003
36	Case report: esophageal collision tumor (oat cell carcinoma and adenocarcinoma) in Barrett's esophagus: immunohistochemical, electron microscopy and LOH analysis. ⁶²	Gonzalez LM...Sanz-Ortega J	12507278	2003
37	Invasive papillary carcinomas of the extrahepatic bile ducts: a clinicopathologic and immunohistochemical study of 13 cases. ⁶²	Hoang MP...Albores-Saavedra J	12481004	2002
38	Retinochoroidal mass: a presenting feature of metastatic oat cell carcinoma of lung. ⁶²	Gupta M...Rennie IG	12510727	2002
39	Synthesis, chemical, radiochemical and radiobiological evaluation of a new 99mTc-labelled bombesin-like peptide. ⁶²	Varvarigou AD...Archimandritis SC	12136524	2002
40	Extrapulmonary oat-cell carcinoma presenting as a primary left ventricular tumor: a case report. ⁶²	Khouzam R...Sethi G	12011814	2002
41	[Oat cell carcinoma of the bladder]. ⁶²	Herrera Puerto J...Isusquiza Garro I	12090189	2002
42	[A case of central diabetes insipidus caused by metastatic small cell lung cancer]. ⁶²	Irifune K...Hiwada K	11974872	2002
43	Combined video-assisted mediastinoscopy and video-assisted thoracoscopy in the management of lung cancer. ⁶²	Mouroux J...Alifano M	11722067	2001
44	[Oat-cell carcinoma of the tongue: report of a case]. ⁶²	Benito J...Perez-Requena J	11526653	2001
45	Paraneoplastic limbic encephalitis associated with bronchogenic carcinoma: a case report. ⁶²	Wani MA...Rehman A	11447443	2001
46	Oat-cell carcinoma of the prostate. Diagnosis, prognosis and therapeutic implications. ⁶²	Lopez Cubillana P...Alonso JD	11598447	2001
47	Metastases to the products of conception from a maternal bronchial carcinoma. A case report and review of literature. ⁶²	Kochman AT...Kowalski P	11769401	2001
48	Lung cancer screening results in the National Cancer Institute New York study. ⁶²	Melamed MR	11147612	2000
49	Primary small cell (oat cell) carcinoma of the breast: report of a case and review of the literature. ⁶²	Yamasaki T...Matsubara O	11107070	2000
50	Bull's eye (target) inclusions in neoplastic cells in malignant serous effusions. A study of 289 cases. ⁶²	Kumar PV...Talei AR	10934946	2000

Sources

Genes for Lung Oat Cell Carcinoma

Genes related to Lung Oat Cell Carcinoma (1 elite genes):

(show all 11)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	RB1	RB Transcriptional Corepressor 1	Protein Coding	425	Pathogenic ⁵ Likely pathogenic ⁵	2594029 25157968
2	TP53	Tumor Protein P53	Protein Coding	28.6	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
3	B2M	Beta-2-Microglobulin	Protein Coding	28.08	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
4	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	25	Likely pathogenic ⁵	25157968 24657128
5	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	25	Likely pathogenic ⁵	26619011
6	PTEN	Phosphatase And Tensin Homolog	Protein Coding	25	Likely pathogenic ⁵	26619011
7	AVP	Arginine Vasopressin	Protein Coding	13.66	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1966564
8	ENO2	Enolase 2	Protein Coding	6.69	DISEASES inferred ¹⁴
9	POMC	Proopiomelanocortin	Protein Coding	6.59	DISEASES inferred ¹⁴
10	SYP	Synaptophysin	Protein Coding	6.08	DISEASES inferred ¹⁴
11	CHGA	Chromogranin A	Protein Coding	6.05	DISEASES inferred ¹⁴

Sources

Variations for Lung Oat Cell Carcinoma

ClinVar genetic disease variations for Lung Oat Cell Carcinoma:

⁵ (show top 50) (show all 106)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	overlap with 54 genes	t(2;2)(p23;p21)(hg19 chr2:g.42552694::ochr2:g.29446394)	INVERS	Pathogenic	487484		GRCh37: 2:29446394-42552694 GRCh38:
2	RB1	NM_000321.3(RB1):c.2242G>T (p.Glu748Ter)	SNV	Pathogenic	13078	rs121913297	GRCh37: 13:49039164-49039164 GRCh38: 13:48465028-48465028
3	RB1	NM_000321.3(RB1):c.1215+1G>A	SNV	Pathogenic	126832	rs587776783	GRCh37: 13:48947629-48947629 GRCh38: 13:48373493-48373493
4	RB1	NM_000321.3(RB1):c.1981C>T (p.Arg661Trp)	SNV	Pathogenic	13087	rs137853294	GRCh37: 13:49033844-49033844 GRCh38: 13:48459708-48459708
5	TP53	NM_000546.6(TP53):c.857A>G (p.Glu286Gly)	SNV	Likely Pathogenic	376590	rs1057519985	GRCh37: 17:7577081-7577081 GRCh38: 17:7673763-7673763
6	RB1	NM_000321.3(RB1):c.2117G>T (p.Cys706Phe)	SNV	Likely Pathogenic	376330	rs121913295	GRCh37: 13:49037877-49037877 GRCh38: 13:48463741-48463741
7	TP53	NM_000546.6(TP53):c.746G>T (p.Arg249Met)	SNV	Likely Pathogenic	376653	rs587782329	GRCh37: 17:7577535-7577535 GRCh38: 17:7674217-7674217
8	TP53	NM_000546.6(TP53):c.518T>G (p.Val173Gly)	SNV	Likely Pathogenic	376016	rs1057519747	GRCh37: 17:7578412-7578412 GRCh38: 17:7675094-7675094
9	TP53	NM_000546.6(TP53):c.821T>A (p.Val274Asp)	SNV	Likely Pathogenic	376675	rs1057520006	GRCh37: 17:7577117-7577117 GRCh38: 17:7673799-7673799
10	TP53	NM_000546.6(TP53):c.839G>T (p.Arg280Ile)	SNV	Likely Pathogenic	161517	rs121912660	GRCh37: 17:7577099-7577099 GRCh38: 17:7673781-7673781
11	TP53	NM_000546.6(TP53):c.577C>A (p.His193Asn)	SNV	Likely Pathogenic	376614	rs876658468	GRCh37: 17:7578272-7578272 GRCh38: 17:7674954-7674954
12	TP53	NM_000546.6(TP53):c.658T>G (p.Tyr220Asp)	SNV	Likely Pathogenic	376689	rs530941076	GRCh37: 17:7578191-7578191 GRCh38: 17:7674873-7674873
13	TP53	NM_000546.6(TP53):c.373A>C (p.Thr125Pro)	SNV	Likely Pathogenic	376666	rs1057520003	GRCh37: 17:7579314-7579314 GRCh38: 17:7675996-7675996
14	TP53	NM_000546.6(TP53):c.577C>G (p.His193Asp)	SNV	Likely Pathogenic	376613	rs876658468	GRCh37: 17:7578272-7578272 GRCh38: 17:7674954-7674954
15	TP53	NM_000546.6(TP53):c.659A>C (p.Tyr220Ser)	SNV	Likely Pathogenic	12383	rs121912666	GRCh37: 17:7578190-7578190 GRCh38: 17:7674872-7674872
16	TP53	NM_000546.6(TP53):c.374C>A (p.Thr125Lys)	SNV	Likely Pathogenic	216465	rs786201057	GRCh37: 17:7579313-7579313 GRCh38: 17:7675995-7675995
17	TP53	NM_000546.6(TP53):c.645T>G (p.Ser215Arg)	SNV	Likely Pathogenic	376661	rs1057520001	GRCh37: 17:7578204-7578204 GRCh38: 17:7674886-7674886
18	TP53	NM_000546.6(TP53):c.856G>C (p.Glu286Gln)	SNV	Likely Pathogenic	376591	rs786201059	GRCh37: 17:7577082-7577082 GRCh38: 17:7673764-7673764
19	TP53	NM_000546.6(TP53):c.731G>T (p.Gly244Val)	SNV	Likely Pathogenic	376601	rs985033810	GRCh37: 17:7577550-7577550 GRCh38: 17:7674232-7674232
20	TP53	NM_000546.6(TP53):c.820G>C (p.Val274Leu)	SNV	Likely Pathogenic	376678	rs1057520005	GRCh37: 17:7577118-7577118 GRCh38: 17:7673800-7673800
21	TP53	NM_000546.6(TP53):c.518T>C (p.Val173Ala)	SNV	Likely Pathogenic	376017	rs1057519747	GRCh37: 17:7578412-7578412 GRCh38: 17:7675094-7675094
22	TP53	NM_000546.6(TP53):c.644G>A (p.Ser215Asn)	SNV	Likely Pathogenic	376662	rs587782177	GRCh37: 17:7578205-7578205 GRCh38: 17:7674887-7674887
23	PTEN	NM_000314.8(PTEN):c.388C>G (p.Arg130Gly)	SNV	Likely Pathogenic	375958	rs121909224	GRCh37: 10:89692904-89692904 GRCh38: 10:87933147-87933147
24	TP53	NM_000546.6(TP53):c.857A>T (p.Glu286Val)	SNV	Likely Pathogenic	376592	rs1057519985	GRCh37: 17:7577081-7577081 GRCh38: 17:7673763-7673763
25	TP53	NM_000546.6(TP53):c.730G>C (p.Gly244Arg)	SNV	Likely Pathogenic	376602	rs1057519989	GRCh37: 17:7577551-7577551 GRCh38: 17:7674233-7674233
26	TP53	NM_000546.6(TP53):c.857A>C (p.Glu286Ala)	SNV	Likely Pathogenic	376593	rs1057519985	GRCh37: 17:7577081-7577081 GRCh38: 17:7673763-7673763
27	PIK3CA	NM_006218.4(PIK3CA):c.1624G>C (p.Glu542Gln)	SNV	Likely Pathogenic	376244	rs121913273	GRCh37: 3:178936082-178936082 GRCh38: 3:179218294-179218294
28	PIK3CA	NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)	SNV	Likely Pathogenic	13659	rs121913274	GRCh37: 3:178936092-178936092 GRCh38: 3:179218304-179218304
29	PIK3CA	NM_006218.4(PIK3CA):c.1625A>C (p.Glu542Ala)	SNV	Likely Pathogenic	376473	rs1057519927	GRCh37: 3:178936083-178936083 GRCh38: 3:179218295-179218295
30	AKT1	NM_001382430.1(AKT1):c.49G>A (p.Glu17Lys)	SNV	Likely Pathogenic	13983	rs121434592	GRCh37: 14:105246551-105246551 GRCh38: 14:104780214-104780214
31	PIK3CA	NM_006218.4(PIK3CA):c.1625A>T (p.Glu542Val)	SNV	Likely Pathogenic	376474	rs1057519927	GRCh37: 3:178936083-178936083 GRCh38: 3:179218295-179218295
32	B2M	NM_004048.4(B2M):c.2T>C (p.Met1Thr)	SNV	Likely Pathogenic	376371	rs1057519879	GRCh37: 15:45003746-45003746 GRCh38: 15:44711548-44711548
33	B2M	NM_004048.4(B2M):c.2T>G (p.Met1Arg)	SNV	Likely Pathogenic	376372	rs1057519879	GRCh37: 15:45003746-45003746 GRCh38: 15:44711548-44711548
34	B2M	NM_004048.4(B2M):c.1A>T (p.Met1Leu)	SNV	Likely Pathogenic	376370	rs1023835002	GRCh37: 15:45003745-45003745 GRCh38: 15:44711547-44711547
35	PIK3CA	NM_006218.4(PIK3CA):c.1625A>G (p.Glu542Gly)	SNV	Likely Pathogenic	376475	rs1057519927	GRCh37: 3:178936083-178936083 GRCh38: 3:179218295-179218295
36	PIK3CA	NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln)	SNV	Likely Pathogenic	375896	rs104886003	GRCh37: 3:178936091-178936091 GRCh38: 3:179218303-179218303
37	PIK3CA	NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly)	SNV	Likely Pathogenic	13656	rs121913274	GRCh37: 3:178936092-178936092 GRCh38: 3:179218304-179218304
38	B2M	NM_004048.4(B2M):c.3G>A (p.Met1Ile)	SNV	Likely Pathogenic	376368	rs1057519877	GRCh37: 15:45003747-45003747 GRCh38: 15:44711549-44711549
39	B2M	NM_004048.4(B2M):c.1A>G (p.Met1Val)	SNV	Likely Pathogenic	376369	rs1023835002	GRCh37: 15:45003745-45003745 GRCh38: 15:44711547-44711547
40	PIK3CA	NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp)	SNV	Likely Pathogenic	217293	rs121913275	GRCh37: 3:178936093-178936093 GRCh38: 3:179218305-179218305
41	PIK3CA	NM_006218.4(PIK3CA):c.1633G>A (p.Glu545Lys)	SNV	Likely Pathogenic	13655	rs104886003	GRCh37: 3:178936091-178936091 GRCh38: 3:179218303-179218303
42	TP53	NM_000546.6(TP53):c.487T>G (p.Tyr163Asp)	SNV	Likely Pathogenic	187052	rs786203436	GRCh37: 17:7578443-7578443 GRCh38: 17:7675125-7675125
43	TP53	NM_000546.6(TP53):c.839G>C (p.Arg280Thr)	SNV	Likely Pathogenic	12368	rs121912660	GRCh37: 17:7577099-7577099 GRCh38: 17:7673781-7673781
44	TP53	NM_000546.6(TP53):c.643A>G (p.Ser215Gly)	SNV	Likely Pathogenic	265337	rs886039484	GRCh37: 17:7578206-7578206 GRCh38: 17:7674888-7674888
45	TP53	NM_000546.6(TP53):c.838A>G (p.Arg280Gly)	SNV	Likely Pathogenic	376658	rs753660142	GRCh37: 17:7577100-7577100 GRCh38: 17:7673782-7673782
46	TP53	NM_000546.6(TP53):c.700T>C (p.Tyr234His)	SNV	Likely Pathogenic	376691	rs864622237	GRCh37: 17:7577581-7577581 GRCh38: 17:7674263-7674263
47	TP53	NM_000546.6(TP53):c.587G>C (p.Arg196Pro)	SNV	Likely Pathogenic	231165	rs483352697	GRCh37: 17:7578262-7578262 GRCh38: 17:7674944-7674944
48	TP53	NM_000546.6(TP53):c.535C>G (p.His179Asp)	SNV	Likely Pathogenic	376610	rs587780070	GRCh37: 17:7578395-7578395 GRCh38: 17:7675077-7675077
49	TP53	NM_000546.6(TP53):c.742C>T (p.Arg248Trp)	SNV	Likely Pathogenic	12347	rs121912651	GRCh37: 17:7577539-7577539 GRCh38: 17:7674221-7674221
50	TP53	NM_000546.6(TP53):c.644G>T (p.Ser215Ile)	SNV	Likely Pathogenic	376660	rs587782177	GRCh37: 17:7578205-7578205 GRCh38: 17:7674887-7674887

Cosmic variations for Lung Oat Cell Carcinoma:

⁸ (show top 50) (show all 1540)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM102042323	ZFHX3	lung,NS,carcinoma,undifferentiated carcinoma	c.-23-8009A>G	p.?	16:72958974-72958974	5
2	COSM87291734	ZFHX3	lung,NS,carcinoma,undifferentiated carcinoma	c.1172A>G	p.Q391R	16:72958974-72958974	5
3	COSM102040476	ZFHX3	lung,NS,carcinoma,undifferentiated carcinoma	c.-23-8037G>T	p.?	16:72959002-72959002	5
4	COSM149314749	ZFHX3	lung,NS,carcinoma,undifferentiated carcinoma	c.1144G>T	p.G382C	16:72959002-72959002	5
5	COSM87290218	ZFHX3	lung,NS,carcinoma,undifferentiated carcinoma	c.1144G>T	p.G382C	16:72959002-72959002	5
6	COSM149318860	ZFHX3	lung,NS,carcinoma,undifferentiated carcinoma	c.1172A>G	p.Q391R	16:72958974-72958974	5
7	COSM126973051	YAP1	lung,NS,carcinoma,undifferentiated carcinoma	c.770C>T	p.P257L	11:102229729-102229729	5
8	COSM145028029	YAP1	lung,NS,carcinoma,undifferentiated carcinoma	c.1154C>T	p.P385L	11:102229729-102229729	5
9	COSM128452039	YAP1	lung,NS,carcinoma,undifferentiated carcinoma	c.1142C>T	p.P381L	11:102229729-102229729	5
10	COSM85237448	YAP1	lung,NS,carcinoma,undifferentiated carcinoma	c.1304C>T	p.P435L	11:102229729-102229729	5
11	COSM143041512	YAP1	lung,NS,carcinoma,undifferentiated carcinoma	c.1316C>T	p.P439L	11:102229729-102229729	5
12	COSM127997731	YAP1	lung,NS,carcinoma,undifferentiated carcinoma	c.1256C>T	p.P419L	11:102229729-102229729	5
13	COSM133274224	YAP1	lung,NS,carcinoma,undifferentiated carcinoma	c.1268C>T	p.P423L	11:102229729-102229729	5
14	COSM90948266	YAP1	lung,NS,carcinoma,undifferentiated carcinoma	c.1202C>T	p.P401L	11:102229729-102229729	5
15	COSM108017622	XRCC6	lung,NS,carcinoma,undifferentiated carcinoma	c.1009A>C	p.I337L	22:41653558-41653558	5
16	COSM95166535	XRCC6	lung,NS,carcinoma,undifferentiated carcinoma	c.1159A>C	p.I387L	22:41653558-41653558	5
17	COSM97230831	XRCC6	lung,NS,carcinoma,undifferentiated carcinoma	c.1159A>C	p.I387L	22:41653558-41653558	5
18	COSM105839764	XRCC6	lung,NS,carcinoma,undifferentiated carcinoma	c.1009A>C	p.I337L	22:41653558-41653558	5
19	COSM106337415	XRCC6	lung,NS,carcinoma,undifferentiated carcinoma	c.1159A>C	p.I387L	22:41653558-41653558	5
20	COSM103711109	XRCC6	lung,NS,carcinoma,undifferentiated carcinoma	c.1036A>C	p.I346L	22:41653558-41653558	5
21	COSM85312404	XRCC1	lung,NS,carcinoma,undifferentiated carcinoma	c.1207A>G	p.M403V	19:43546970-43546970	5
22	COSM134125623	XRCC1	lung,NS,carcinoma,undifferentiated carcinoma	c.1114A>G	p.M372V	19:43546970-43546970	5
23	COSM100781761	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.724A>T	p.K242*	11:32392044-32392044	5
24	COSM111539040	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.1309A>T	p.K437*	11:32392044-32392044	5
25	COSM149728755	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.437G>A	p.W146*	11:32434909-32434909	5
26	COSM130518653	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.673A>T	p.K225*	11:32392044-32392044	5
27	COSM113475703	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.437G>A	p.W146*	11:32434909-32434909	5
28	COSM111529696	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.437G>A	p.W146*	11:32434909-32434909	5
29	COSM113484991	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.1360A>T	p.K454*	11:32392044-32392044	5
30	COSM147414475	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.437G>A	p.W146*	11:32434909-32434909	5
31	COSM149739953	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.1360A>T	p.K454*	11:32392044-32392044	5
32	COSM148580942	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.437G>A	p.W146*	11:32434909-32434909	5
33	COSM148593279	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.1360A>T	p.K454*	11:32392044-32392044	5
34	COSM91372655	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.437G>A	p.W146*	11:32434909-32434909	5
35	COSM91383011	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.1360A>T	p.K454*	11:32392044-32392044	5
36	COSM147426277	WT1	lung,NS,carcinoma,undifferentiated carcinoma	c.1309A>T	p.K437*	11:32392044-32392044	5
37	COSM124478343	WNT8A	lung,NS,carcinoma,undifferentiated carcinoma	c.422G>C	p.G141A	5:138088927-138088927	5
38	COSM104050903	WNT8A	lung,NS,carcinoma,undifferentiated carcinoma	c.368G>C	p.G123A	5:138088927-138088927	5
39	COSM105123686	WNT10B	lung,NS,carcinoma,undifferentiated carcinoma	c.*288A>C	p.?	12:48966259-48966259	5
40	COSM87652733	WNT10B	lung,NS,carcinoma,undifferentiated carcinoma	c.1006A>C	p.K336Q	12:48966259-48966259	5
41	COSM102763785	WNT10B	lung,NS,carcinoma,undifferentiated carcinoma	c.*288A>C	p.?	12:48966259-48966259	5
42	COSM99767946	USP5	lung,NS,carcinoma,undifferentiated carcinoma	c.755C>T	p.T252I	12:6856877-6856877	5
43	COSM84601598	USP5	lung,NS,carcinoma,undifferentiated carcinoma	c.755C>T	p.T252I	12:6856877-6856877	5
44	COSM121848752	USP38	lung,NS,carcinoma,undifferentiated carcinoma	c.994G>C	p.A332P	4:143197868-143197868	5
45	COSM88410243	USP38	lung,NS,carcinoma,undifferentiated carcinoma	c.994G>C	p.A332P	4:143197868-143197868	5
46	COSM87541563	USP32	lung,NS,carcinoma,undifferentiated carcinoma	c.192T>A	p.I64=	17:60301699-60301699	5
47	COSM99795256	USP32	lung,NS,carcinoma,undifferentiated carcinoma	c.192T>A	p.I64=	17:60301699-60301699	5
48	COSM143996084	UHRF1	lung,NS,carcinoma,undifferentiated carcinoma	c.1620C>G	p.F540L	19:4947122-4947122	5
49	COSM143964403	UHRF1	lung,NS,carcinoma,undifferentiated carcinoma	c.1428C>G	p.F476L	19:4947122-4947122	5
50	COSM145430147	UHRF1	lung,NS,carcinoma,undifferentiated carcinoma	c.1467C>G	p.F489L	19:4947122-4947122	5

Sources

Expression for Lung Oat Cell Carcinoma

Search GEO for disease gene expression data for Lung Oat Cell Carcinoma.

Sources

Pathways for Lung Oat Cell Carcinoma

Pathways related to Lung Oat Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 64)

#	Super pathways	Score	Top Affiliating Genes
1	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.59	TP53 RB1 PTEN POMC PIK3CA B2M
2	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.21	TP53 POMC PIK3CA B2M AKT1
3	Malignant pleural mesothelioma ⁷⁴	12.6	TP53 PTEN PIK3CA AKT1
4	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.54	TP53 RB1 PIK3CA AKT1
5	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.53	AKT1 PIK3CA PTEN RB1 TP53
6	Neuroscience ³	12.48	SYP POMC ENO2 AVP
7	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.34	TP53 PTEN PIK3CA AKT1
8	Focal adhesion ⁷⁴	12.2	PTEN PIK3CA AKT1
9	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.2	AKT1 PIK3CA PTEN RB1 TP53
10	PDGFR-beta signaling pathway ⁶¹ Show member pathways ErbB1 downstream signaling ⁶¹	12.19	PTEN PIK3CA AKT1
11	Development IGF-1 receptor signaling ²² Show member pathways Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.11	TP53 PTEN PIK3CA AKT1
12	Epithelial to mesenchymal transition in colorectal cancer ⁷⁴	12.09	TP53 PIK3CA AKT1
13	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.06	TP53 RB1 PTEN AKT1
14	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	12.04	PTEN PIK3CA AKT1
15	AMP-activated protein kinase signaling ⁷⁴ Show member pathways AMPK Signaling Pathway ⁶⁷ Leptin and adiponectin ⁷⁴	12.03	TP53 PIK3CA AKT1
16	miRNA regulation of DNA damage response ⁷⁴ Show member pathways DNA damage response ⁷⁴	12.02	TP53 RB1 AKT1
17	mTOR Signaling ⁶⁵	12.01	AKT1 PTEN TP53
18	GDNF signaling ⁷⁴	11.99	SYP PTEN AKT1
19	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	11.99	TP53 RB1 PTEN PIK3CA AKT1
20	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	11.98	TP53 PTEN PIK3CA AKT1
21	Direct p53 effectors ⁶¹	11.97	TP53 RB1 PTEN
22	Integrated breast cancer pathway ⁷⁴	11.96	TP53 RB1 PTEN AKT1
23	MAPK Pathway ⁷⁰ Show member pathways Toll-like Receptor Pathway ⁷⁰	11.94	TP53 PIK3CA AKT1
24	Development EPO-induced Jak-STAT pathway ²² Show member pathways EPO receptor signaling ⁷⁴ Signaling events mediated by Stem cell factor receptor (c-Kit) ⁶¹	11.92	PTEN PIK3CA AKT1
25	Development EGFR signaling via small GTPases ²² Show member pathways Development EGFR signaling via PIP3 ²² Development PDGF signaling via MAPK cascades ²²	11.89	AKT1 PIK3CA PTEN
26	Gastrin signaling pathway ⁷⁴	11.89	AKT1 CHGA PIK3CA
27	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.87	TP53 POMC AKT1
28	Senescence and autophagy in cancer ⁷⁴	11.86	TP53 RB1 PTEN
29	DNA damage response (only ATM dependent) ⁷⁴	11.84	TP53 PTEN PIK3CA
30	PI3K / Akt Signaling ³	11.78	PTEN PIK3CA AKT1
31	TP53 Regulates Metabolic Genes ⁶⁶	11.75	TP53 PTEN AKT1
32	Clear cell renal cell carcinoma pathways ⁷⁴	11.73	AKT1 ENO2 PTEN
33	Thyroid hormones production and peripheral downstream signaling effects ⁷⁴	11.72	TP53 POMC PIK3CA
34	mTOR Pathway ⁷⁰ Show member pathways TGF-beta Pathway ⁷⁰	11.69	TP53 PIK3CA AKT1
35	Glucocorticoid receptor regulatory network ⁶¹	11.67	TP53 POMC AKT1
36	p75(NTR)-mediated signaling ⁶¹ Show member pathways Ceramide signalling ⁶⁶ NFG and proNGF binds to p75NTR ⁶⁶	11.59	TP53 PIK3CA AKT1
37	BCR signaling pathway ⁶¹	11.58	PTEN PIK3CA AKT1
38	IL-2 Gene Expression in Activated and Quiescent T-Cells ⁶⁴ Show member pathways TOB in T-Cell Signaling ⁶⁴	11.55	RB1 PIK3CA AKT1
39	Prader-Willi and Angelman syndrome ⁷⁴	11.54	TP53 RB1 POMC
40	Thyroid stimulating hormone (TSH) signaling pathway ⁷⁴	11.52	AKT1 PIK3CA RB1
41	Netrin-UNC5B signaling pathway ⁷⁴	11.46	TP53 PIK3CA AKT1
42	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.42	TP53 PTEN PIK3CA AKT1
43	Microtubule cytoskeleton regulation ⁷⁴	11.39	PTEN PIK3CA AKT1
44	Small cell lung cancer ⁷⁴	11.34	TP53 RB1 PTEN PIK3CA AKT1
45	Copper homeostasis ⁷⁴ Show member pathways Copper metabolism ⁷⁴ Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1) ⁶⁶	11.32	TP53 PTEN PIK3CA AKT1
46	VEGFR1 specific signals ⁶¹	11.13	PIK3CA AKT1
47	VEGFR3 signaling in lymphatic endothelium ⁶¹	11.11	PIK3CA AKT1
48	PI3K-AKT-mTOR signaling pathway and therapeutic opportunities ⁷⁴	11.11	PTEN PIK3CA AKT1
49	Plasma membrane estrogen receptor signaling ⁶¹	11.1	PIK3CA AKT1
50	Dravet syndrome ⁷⁴	11.08	AKT1 PIK3CA

Sources

GO Terms for Lung Oat Cell Carcinoma

Biological processes related to Lung Oat Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 11)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of gene expression	GO:0010629	10.04	TP53 RB1 PIK3CA AKT1
2	positive regulation of peptidyl-serine phosphorylation	GO:0033138	9.91	PIK3CA AVP AKT1
3	negative regulation of epithelial cell proliferation	GO:0050680	9.85	B2M PTEN RB1
4	maternal behavior	GO:0042711	9.78	PTEN AVP
5	anoikis	GO:0043276	9.76	PIK3CA AKT1
6	negative regulation of neuron death	GO:1901215	9.73	ENO2 CHGA AKT1
7	cell population proliferation	GO:0008283	9.72	TP53 RB1 PTEN AKT1
8	negative regulation of glial cell proliferation	GO:0060253	9.71	TP53 RB1
9	protein kinase B signaling	GO:0043491	9.63	PTEN PIK3CA AKT1
10	phosphatidylinositol 3-kinase signaling	GO:0014065	9.43	PTEN PIK3CA AKT1
11	cellular response to decreased oxygen levels	GO:0036294	8.8	PTEN AKT1